This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -132.98% and -96.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -22.62% and 2.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.
Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
by Zacks Equity Research
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
Recent Price Trend in Arvinas, Inc. (ARVN) is Your Friend, Here's Why
by Zacks Equity Research
Arvinas, Inc. (ARVN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.
Analysts Estimate Arvinas, Inc. (ARVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Arvinas, Inc. (ARVN) Rating Upgrade to Buy
by Zacks Equity Research
Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arvinas, Inc. (ARVN) Moves 13% Higher: Will This Strength Last?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy
by Zacks Equity Research
Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates
by Zacks Equity Research
Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.